灵芝多糖对糖尿病肾病小鼠肾小管上皮细胞间充质转化的抑制作用
2020-04-03钟涛张国新周迪夷
钟涛 张国新 周迪夷



[摘要] 目的 探讨灵芝多糖对糖尿病肾病(DN)小鼠肾小管上皮细胞间充质转化(EMT)的影响。 方法 将40只C57BL/KsJ-db/db小鼠按体重随机分为5组,每组8只。正常组给予普通饲料喂养。模型组、灵芝多糖(GLP)低(100 mg/kg)、高(400 mg/kg)剂量组和厄贝沙坦组(50 mg/kg)给予高糖饲料喂养,DN小鼠造模成功后,各组每日灌胃给药,持续8周,测定各组小鼠肾功能、血脂等生理指标变化;取肾组织HE染色观察GLP对小鼠肾脏病理改变的影响,用Western blot和实时荧光定量PCR实验检测E-cadherin、α-SMA、TGF-β1、Fibronectin、Vimentin、N-cadherin、p-Smad2、p-Smad3、Smad2、Smad3蛋白表达及mRNA水平。 结果 与模型组比较,GLP低、高剂量组血脂代谢及肾功能升高(P < 0.05)。与模型组比较,GLP低、高剂量组及厄贝沙坦组E-cadherin蛋白及mRNA水平升高,而α-SMA、Fibronectin、Vimentin、N-cadherin蛋白及mRNA水平降低(P < 0.01)。Smad2、Smad3总蛋白表达水平无变化。 结论 GLP可能通过调节TGF-β1/Smad信号通路,抑制DN小鼠的EMT。
[关键词] 灵芝多糖;上皮细胞-间充质转化;糖尿病肾病;TGF-β1/Smad信号通路
[中图分类号] R587.24 [文献标识码] A [文章编号] 1673-7210(2020)02(c)-0009-04
[Abstract] Objective To investigate the effect of ganoderma lucidum polysaccha-ride (GLP) on epithelial-to-mysenchymal transition (EMT) of renal tubular epithelial cells in diabetic nephropathy (DN) mice. Methods Forty C57BL/KsJ-db/db mice were randomly divided into 5 groups by weight. Normal group was fed with normal feed. Model group, GLP low (100 mg/kg), high (400 mg/kg) dose groups and Irbesartan group (50 mg/kg, Irbesartan) were given high-sugar dieat. Each group was given the drug by gavage daily for 8 weeks after successful modeling of DN mice. The changes of renal function, blood lipid and other physiological indexes were measured. The protein expression and mRNA level of E-cadherin, α-SMA, TGF-β1, Fibronectin, Vimentin, N-cadherin, TGF-β1, p-Smad2, p-Smad3, Smad2 and Smad3 were measured by Western Blot and Real-time PCR. Results Compared with the model group, the renal function and blood lipid metabolism in GLP low and high doses group were significantly decreased (P < 0.05). Compared with the model group, the levels of E-cadherin protein and mRNA were increased in the GLP low and high doses group and the Irbesartan group, while the levels of α-SMA, Fibronectin, Vimentin, N-cadherin protein and mRNA were decreased (P < 0.01). The expression levels of Smad2 and Smad3 were unchanged. Conclusion GLP inhibits EMT maybe via inhibition of TGF-β1/Smad signaling pathway.
[Key words] Ganoderma lucidum polysaccharide; Endothelial to mesenchymal transition; Diabetic nephropathy; TGF-β1/Smad signaling pathway
糖尿病腎病(diabetic nephropathy,DN)是糖尿病最常见的严重的微血管病变并发症[1-2],肾间质纤维化是其主要病理变化之一[3],其初始环节之一是肾小管上皮-间充质转化(endothelial to mesenchymal transition,EMT)[4-5],而转化生长因子-β1(TGF-β1)是其发生的重要诱导因子[6]。灵芝多糖(ganoderma lucidum polysaccharide,GLP)具有降血糖、免疫调节等活性[7-8]。因此,本研究通过给予DN动物模型不同剂量的GLP,观察GLP对DN的保护作用,从TGF-β1/Smad通路探讨其机制。
1 材料与方法
1.1 实验动物
SPF级2型糖尿病(T2DM)模型C57BL/KsJ-db/db雄性小鼠40只,购于上海斯莱克动物实验有限公司,动物生产许可证号:SCXK(沪)2017-0015。饲养于浙江中医藥大学动物实验研究中心,实验饲养室许可证号SYXK(浙)2013-0184。动物饲养条件:温度(25±1)℃,相对湿度50%~70%。
1.2 试剂与药品
GLP,纯度>95%杭州众芝康菇生物技术有限公司(Johncan International),批号:GK221020。
1.3 方法
1.3.1 动物造模及给药 适应性喂养2周后,32只小鼠给予高糖高热量饲料,另8只小鼠,作为正常组,给予普通饲料喂养。1……
